Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial

Bossa, Fabrizio; Fiorella, Serafina; Caruso, Nazario; Accadia, Laura; Napolitano, Grazia; Valvano, Maria Rosa; Andriulli, Angelo; Annese, Vito
March 2007
American Journal of Gastroenterology;Mar2007, Vol. 102 Issue 3, p601
Academic Journal
BACKGROUND: In patients with severe attacks of ulcerative colitis (UC), IV steroids represent the first-line treatment, leading to clinical improvement in approximately 50–60% of patients. AIM: The aim of this study was to prospectively compare the efficacy and safety of different modalities of steroid administration, and to evaluate predictors of failure to therapy. MATERIALS In a single-center, double-blind trial, consecutive patients with a severe attack of UC received AND METHODS: 1 mg/kg/day of 6-methyl-prednisolone administered randomly by either a bolus injection (group A) or continuous infusion (group B). RESULTS: Sixty-six patients were enrolled (35 men, mean age 38 ± 15, range 18–75 yr), 15 of them at their first attack of UC; in the remaining cases, the mean duration of disease was 4.5 ± 5 yr. At inclusion, forty patients (60%) had pancolitis and the remainder had left-sided colitis. Overall, thirty-three patients (50%) underwent clinical remission after 7 days of treatment: 16 of 32 in group A and 17 of 34 in group B. Thirty-one patients eventually underwent total colectomy (12 in group A and 9 in group B), which was carried out by the first month in 10 patients (5 in each group). Twenty-eight patients (15 in group A and 13 in group B) experienced steroid-related adverse reactions. All differences between groups were not statistically significant. Previous use of steroids (OR 13.6, CI 2–86) and active smoking (OR 11.6, CI 1.4–107) were independent predictors of nonresponse. CONCLUSIONS: In severe attacks of UC, methyl-prednisolone given as a continuous infusion was no better than bolus administration in terms of efficacy and safety.


Related Articles

  • Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study. Bossa, Fabrizio; Latiano, Anna; Rossi, Luigia; Magnani, Mauro; Palmieri, Orazio; Dallapiccola, Bruno; Serafini, Sonja; Damonte, Gianluca; De Santo, Ermelinda; Andriulli, Angelo; Annese, Vito // American Journal of Gastroenterology;Oct2008, Vol. 103 Issue 10, p2509 

    BACKGROUND AND AIM: Nearly 25% of patients with ulcerative colitis (UC) requiring steroids therapy become steroid-dependent after 1 yr, and virtually all develop steroid-related adverse events. We planned a controlled study to investigate the efficacy and safety of dexamethasone 21-P (Dex 21-P)...

  • Dramatic And Long Lasting Efficiency (13 Years) Of Oral 5 Aspirin. Maroy, Bernard // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p12 

    Introduction: Could 5 ASA be an option in case of cortico-resistant and/or intolerant ulcerative colitis? Case report: A 55-year-old woman was referred for a recent, moderately severe, left-sided ulcerative colitis. The response to corticotherapy was initially fair, then mediocre, complicated by...

  • The Microvacular Thrombi of Colonic Tissue in Ulcerative Colitis. Guobin He; Qin Ouyang; Daiyun Chen; Fengyuan Li; Jingguo Zhou // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2236 

    Abstract  Mucosal microvacular thrombi in rectal biopsies were observed in some ulcerative colitis (UC). Heparin may be effective in steroid resistant UC in some studies, however, the new results of meta-analysis demonstrated a non-significant effect of heparin in controlled...

  • The Role of Zinc and Metallothionein in the Dextran Sulfate Sodium-Induced Colitis Mouse Model. C. Tran; S. Sundar; P. Coyle // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2113 

    Abstract  Zinc (Zn) and its binding protein metallothionien (MT) have been proposed to suppress the disease activity in ulcerative colitis. To determine the role of Zn and MT in the dextran sulfate sodium (DSS)-induced model of colitis in mice, a DSS dose-response study was...

  • Leukocytapheresis (LCAP) in the Management of Chronic Active Ulcerative Colitis—Results of a Randomized Pilot Trial. Jörg Emmrich; Sebastian Petermann; Dietrich Nowak; Ingolf Beutner; Peter Brock; Patrick Mausfeld-Lafdhiya; Stefan Liebe; Wolfgang Ramlow // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2044 

    Abstract  Recent studies suggest that leukocytapheresis with Cellsorba is a valuable therapy for ulcerative colitis after failure of conventional treatment. In this study the potential of leukocytapheresis to induce remission in refractory chronic colitis under the conditions of...

  • Meta-Analysis of the Placebo Response in Ulcerative Colitis. Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily Levitan; Ciaran Kelly // Digestive Diseases & Sciences;Apr2008, Vol. 53 Issue 4, p875 

    Abstract   Purpose The placebo response rate in randomized controlled trials (RCTs) in ulcerative colitis (UC) varies from 0 to 76%. The aims of this study were to quantify the pooled placebo response rate and identify the factors affecting it. Methods We performed a...

  • Abnormalities in colonic mucin may contribute to the persistence of colonic mucosal inflammation.  // Journal of Gastroenterology;2000, Vol. 35 Issue 1, p71 

    Editorial. Deals with the possible contribution of the abnormalities in colonic mucin to the persistence of colonic mucosal inflammation. Percentage of ulcerative colitis patients with circulating antibodies to colonocytes; Number of reported mucin genes; Description of MUC2 mucin; Candidate...

  • A Population-based Ecologic Study of Inflammatory Bowel Disease: Searching for Etiologic Clues. Chris Green; Lawrence Elliott; Carole Beaudoin; Charles N. Bernstein // American Journal of Epidemiology;Oct2006, Vol. 164 Issue 7, p615 

    The authors' objective in this study was to determine geographic variations in the incidence of inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis, in the Canadian province of Manitoba and its association with the sociodemographic, geographic, and...

  • Aminosalicylate (Major drug group).  // Royal Society of Medicine: Medicines;2002, p52 

    The article provides information on aminosalicylate agents, a chemical class of drugs that contain a 5-aminosalicylic acid component. They are used to maintain remission of the symptoms of ulcerative colitis, also to treat active Crohn's disease; also, they can be used to treat rheumatoid...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics